VERU INC.

Veru Inc. announced the completion of enrollment in its Phase 2b PLATEAU clinical study for enobosarm, which exceeded the targeted 200 patients. The trial evaluates the effect of oral enobosarm 3 mg versus placebo in older patients with obesity who are initiating semaglutide treatment. Interim analysis results are anticipated in the first quarter of 2027, with final topline data expected in the fourth quarter of 2027.

Veru Inc. announced it will present at the 2026 4th Annual Obesity & Weight Loss Drug Development Summit, highlighting its enobosarm program for cardiometabolic and inflammatory diseases. The company's CEO and CSO will deliver presentations on July 14-15, 2026, focusing on combining GLP-1s with Selective Androgen Receptor Modulators (SARMs) to prevent muscle loss in sarcopenic obesity and advancing regulatory strategies. The update also detailed the ongoing Phase 2b PLATEAU clinical study and positive results from the completed Phase 2b QUALITY study for enobosarm.

Veru Inc. has established an "at the market" equity offering program by entering into a Sales Agreement with Oppenheimer & Co. Inc. and Canaccord Genuity LLC. This agreement, effective July 2, 2026, allows the company to sell up to $21,800,000 of its common stock from time to time. The company will pay the sales agents a commission of 3.0% on the gross proceeds from each sale.

Veru Inc. announced a clinical supply agreement with Novo Nordisk A/S for its Phase 2b PLATEAU clinical study. The study will evaluate Veru's enobosarm in combination with Novo Nordisk's Wegovy for weight reduction in older adults with obesity. Veru will sponsor and conduct the study, while Novo Nordisk will supply Wegovy at no charge. Veru retains global rights to enobosarm but granted Novo Nordisk a right of first negotiation for future collaborations involving enobosarm with Novo Nordisk GLP-1 products.

VERU INC. reported a net loss of $(2.74) million for the three months ended March 31, 2026, a significant improvement from $(7.90) million in the prior year. The company's cash, cash equivalents, and restricted cash increased to $27.6 million from $15.8 million at September 30, 2025, primarily due to a public offering that generated $23.4 million. Despite the improved cash position, management has concluded that substantial doubt exists regarding its ability to continue as a going concern for the next twelve months, citing insufficient capital to fund operations. The company is prioritizing the development of enobosarm, with sabizabulin advancement contingent on securing additional funding.

Veru Inc. announced its fiscal Q2 2026 financial results, reporting a significant reduction in net loss to $2.7 million, or $0.12 per share, compared to $7.9 million, or $0.54 per share, in the prior year. The company also provided an update on its Phase 2b PLATEAU clinical study for enobosarm + semaglutide, confirming active enrollment and an interim analysis expected in Q1 2027. Cash, cash equivalents, and restricted cash increased to $27.6 million.

Veru Inc. announced its fiscal 2026 second quarter financial results, reporting a significant reduction in net loss to $2.7 million, or $0.12 per share, compared to $7.9 million, or $0.54 per share, in the prior year's quarter. The company also provided a corporate update, highlighting that the Phase 2b PLATEAU clinical study, evaluating enobosarm + semaglutide for higher quality weight reduction, is actively enrolling and on track for interim analysis in the first quarter of calendar year 2027.

Veru Inc. announced it will host a conference call and audio webcast on Wednesday, May 13, 2026, to discuss its fiscal 2026 second quarter financial results and provide a business update. The company also provided updates on its late-stage drug development programs, enobosarm and sabizabulin. The Phase 2b PLATEAU clinical study for enobosarm is enrolling, with interim data expected in Q1 2027 and final data in Q4 2027, building on positive results from the completed Phase 2b QUALITY study.